Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Protac activity at VHL/ERRalpha in human MCF7 cells relative to control
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Protac activity at VHL/ERRalpha in human MCF7 cells
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Binding Assay from US Patent US11285226: "Aryl ethene derivative and pharmaceutical composition containing same as active ingredient"
Assay data:32 Active, 32 Activity ≤ 1 µM, 32 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Binding Assay from US Patent US10934303: "Aryl ethene derivative and pharmaceutical composition containing same as active ingredient"
Assay data:28 Active, 13 Activity ≤ 1 µM, 28 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
Assay data:28 Active, 28 Activity ≤ 1 µM, 28 Tested
Radioligand Displacement Assay from Article 10.1016/j.bbrc.2008.06.050: "ERRgamma tethers strongly bisphenol A and 4-alpha-cumylphenol in an induced-fit manner."
Assay data:3 Active, 3 Activity ≤ 1 µM, 4 Tested
ERRgamma FRET Assay from Article 10.1021/jm050161j: "Identification and structure-activity relationship of phenolic acyl hydrazones as selective agonists for the estrogen-related orphan nuclear receptors ERRbeta and ERRgamma."
Assay data:7 Active, 5 Activity ≤ 1 µM, 7 Tested
Radioligand Displacement Assay from Article 10.1016/j.bmcl.2005.11.030: "Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRgamma."
Assay data:11 Active, 1 Activity ≤ 1 nM, 11 Activity ≤ 1 µM, 11 Tested
Fluorescence Energy Transfer (FRET) Measurement from Article 10.1074/jbc.M703337200: "Crystal structure of human estrogen-related receptor alpha in complex with a synthetic inverse agonist reveals its novel molecular mechanism."
Assay data:2 Active, 2 Activity ≤ 1 µM, 2 Tested
Competitive Radioligand-Binding Assay from US Patent US9604931: "Nuclear receptor binding agents"
Assay data:12 Active, 1 Activity ≤ 1 nM, 12 Activity ≤ 1 µM, 12 Tested
Modulation of ERRgamma (unknown origin) expressed in MG63 cells assessed as transcriptional activity up to 7.9 uM incubated for 18 hrs by dual-Glo luciferase assay relative to control
Agonist activity at recombinant full-length human ERRalpha expressed in MG63 cells assessed as transcriptional activation incubated for 18 hrs by dual-Glo luciferase assay relative to control
Assay data:13 Tested
Agonist activity at recombinant full-length human ERRalpha expressed in MG63 cells assessed as transcriptional activation incubated for 18 hrs by dual-Glo luciferase assay
Assay data:4 Active, 13 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Inhibition of FITC-RIP140 peptide binding to N-terminal His-tagged human GST-ERRalpha-LBD (290 to 519 residues) expressed in Escherichia coli incubated for 4 hrs by fluorescence polarization assay
Assay data:12 Active, 11 Activity ≤ 1 µM, 13 Tested
Inhibition of FITC-RIP140 peptide binding to N-terminal His-tagged human GST-ERRalpha-LBD (290 to 519 residues) expressed in Escherichia coli incubated for 4 hrs by fluorescence polarization assay relative to control
Assay data:12 Tested
Inverse agonist activity at ERRgamma in human BHP10-3SCp cells assessed as increase in [131-I] uptake at 12 uM in presence of NIS-specific inhibitor, KClO4
Inverse agonist activity at ERRgamma in human BHP10-3SCp cells assessed as increase in [131-I] uptake
Inverse agonist activity at ERRgamma in human BCPAP cells assessed as increase in p42 MAPK phosphorylation at 6 to 12 uM by immunoblot analysis
Assay data:1 Active, 1 Tested
Inverse agonist activity at ERRgamma in human BCPAP cells assessed as increase in p44 MAPK phosphorylation at 6 to 12 uM by immunoblot analysis
Inverse agonist activity at ERRgamma in human CAL-62 cells assessed as increase in p44 MAPK phosphorylation at 6 to 12 uM by immunoblot analysis
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on